Effect of exogenous growth hormone on the outcomes of IVF-ET for polycystic ovary syndrome patients
WU Zhengzhong1 LI Xuemei1 CHENG Yanjun1 LIU Lanyun2 QIN Chunrong1▲
1.Department of Reproduction Center， Shenzhen Maternal ＆ Child Healthcare Hospital Affiliated to Southern Medical University, Guandong Province, Shenzhen 518000, China;
2.Department of Obstetrics, Maternal ＆ Child Health Care Hospital of Longgang District in Shenzhen, Guandong Province, Shenzhen 518000, China
Abstract：Objective To investigate the effect of exogenous growth hormone (GH) pretreatment on the outcomes of in vitro fertilization-embryo transfer (IVF-ET) in patients with polycystic ovary syndrome (PCOS). Methods From July 2016 to August 2018, 120 cases with PCOS who undergoing their first IVF-ET in the Department of Reproduction Center of Shenzhen Maternal ＆ Child Healthcare Hospital Affiliated to Southern Medical University were selected as objects. The patients were divided into treatment group (68 patients) and control group (52 patients) according to whether exogenous GH was used during ovulation induction. The laboratory indicators and clinical outcomes between two groups were compared. Results The total dosage of gonadotropins and the days of gonadotropins stimulation in treatment group were lower than those in control group (all P < 0.05), while endometrial thickness on the day of ovum pick-up, the normal fertilization rate, high-quality embryo formation rate, clinical pregnancy rate and live birth rate in treatment group were higher than those in control group (all P < 0.05). There were no statistically significant differences between the two groups in the incidence of moderate to severe ovarian hyperstimulation syndrome, the number of retrieved oocytes, the cleavage rate, embryo transfer day intrauterine membrane thickness and abortion rate (P > 0.05). Conclusion The pretreatment with exogenous GH helps to improve the outcome of IVF-ET in PCOS patients.
[1] Zhu X，Ye H，Fu Y. The utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments [J]. Medicine（Baltimore），2016，95（28）：e4193.
[2] Zhang Y，Liu LY，Yin TL，et al. Follicular metabolic changes and effects on oocyte quality in polycystic ovary syndrome patients [J]. Oncotarget，2017，8（46）：80472-80480.
[3] Dosouto C，Calaf J，Polo A，et al. Growth hormone and reproduction：lessons learned from animal models and clinical trials [J]. Front Endocrinol（Lausanne），2019，10：404.
[4] Safdarian L，Aghahosseini M，Alyasin A，et al. Growth Hormone（GH）Improvement of Ovarian Responses and Pregnancy Outcome in Poor Ovarian Responders：A Randomized Study [J]. Asian Pac J Cancer Prev，2019，20（7）：2033-2037.
[5] Lee YX，Shen MS，Tzeng CR，et al. Low Dose Growth Hormone Adjuvant Treatment With Ultra-Long Ovarian Stimulation Protocol in Poor Responders Showed Non-inferior Pregnancy Outcome Compared With Normal Responders [J]. Front Endocrinol（Lausanne），2019，10：892.
[6] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Wor-kshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome（PCOS）[J]. Hum Reprod，2004，19（1）：41-47.
[7] 吴正中，李雪梅，林碎玲，等.卵巢窦卵泡数对不同年龄段多囊卵巢综合征患者的临床诊断价值[J].生殖医学杂志，2019，28（10）：1168-1172.
[8] ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. The Vienna consensus：report of an expert meeting on the development of ART laboratory performance indicators [J]. Reprod Biomed Online，2017，35（5）：494-510.
[9] 孙青，黄国宁，孙海翔，等.胚胎实验室关键指标质控专家共识[J].生殖医学杂志，2018，29（9）：836-851.
[10] 李肖肖，王珊，于彩虹，等.生长激素对IVF-ET结局影响的研究进展[J].中国计划生育学杂志，2017，25（2）：141-144.
[11] de Boer JA，Schoemaker J，van der Veen EA. Impaired Reproductive Function in Women Treated for Growth Hormone Deficiency During Childhood [J]. Clin Endocrinol（Oxf），1997，46（6）：681-689.
[12] Giampietro A，Milardi D，Bianchi A，et al. The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency：report of four cases and review of the literature [J]. Fertil Steril，2009，91（3）：930.e7-e11.
[13] Homburg R，Levy T，Ben-Rafael Z. Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome：a randomized，double-blind，placebo controlled trial [J]. Hum Reprod，1995，10（10）：2550-2553.
[14] Krishnan A，Muthusami S. Hormonal alterations in PCOS and its influence on bone metabolism [J]. J Endocrinol，2017，232（2）：R99-R113.
[15] 刘珍，安锦霞.人生长激素在多囊卵巢综合征患者的体外受精超排卵中的应用价值[J].生殖医学杂志，2011， 20（4）：280-283.
[16] Bosch E，Labarta E，Kolibianakis E，et al. Regimen of Ovarian Stimulation Affects Oocyte and Therefore Embryo Quality [J]. Fertil Steril，2016，105（3）：560-570.
[17] Xu YM，Hao GM，Gao BL. Application of Growth Hormone in in vitro Fertilization [J]. Front Endocrinol（Lausanne），2019，10：502.
[18] Cui N，Li AM，Luo ZY，et al. Effects of growth hormone on pregnancy rates of patients with thin endometrium [J]. J Endocrinol Invest，2019，42（1）：27-35.
[19] Reyes-Mu?觡oz E，Sathyapalan T，Rossetti P，et al. Polycystic Ovary Syndrome：Implication for Drug Metabolism on Assisted Reproductive Techniques-A Literature Review [J]. Adv Ther，2018，35（11）：1805-1815.
[20] Zhang B，Shozu M，Okada M，et al. Insulin-like Growth Factor I Enhances the Expression of Aromatase P450 by Inhibiting Autophagy [J]. Endocrinology，2010，151（10）：4949-4958.
[21] Wang XM，Jiang H，Zhang WX，et al. The effects of growth hormone on clinical outcomes after frozen-thawed embryo transfer [J]. Int J Gynaecol Obstet，2016，133（3）：347-350.
2020, Vol. 17 
京公网安备 11010502046598号